Xiaobin Ma
17 Papers
Xiaobin Ma is an academic researcher. The author has contributed to research in topics: Medicine & Nanocarriers. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
On-demand targeting nanotheranostics with stimuli-responsive releasing property to improve delivery efficiency to cancer.
Hongwei Lu,Ji Cheng Xu,Jinfan Yang,Zhongling Wang,Pengfu Xu,Qian Hao,Wen Luo,Shuaijun Li,Zhengqing Li,Xiangdong Xue,Hongbo Zheng,Zhangjian Zhou,Hao Wu,Xiaobin Ma,Yuanpei Li +14 more
TL;DR: In this article , a smart on-demand targeting nanotheranostic system with stimuli-responsive releasing property was proposed to improve the delivery efficiency for ovarian cancer by preventing premature drug leakage via boronate ester linkages and shielding the targeting moieties from non-specific binding when circulating in the blood.
21
Programmed-response cross-linked nanocarrier for multidrug-resistant ovarian cancer treatment.
Haijing Qu,Jinfan Yang,Shuaijun Li,Ji Yan Xu,Xin Zhou,Xiangdong Xue,Dalin Zhang,Hongxu Du,Yingbin Shen,Mythili Ramachandran,Hongbo Zheng,Yi Wu,Hao Wu,Xiaobin Ma,Tzu-yin Lin,Yuanpei Li +15 more
TL;DR: In this article , a programable-released disulfide cross-linked micelle (PDCM) was used to deliver the antitumor drug betulinic acid (BA) and paclitaxel.
9
Breast cancer is associated with coronary heart disease: a cross-sectional survey of NHANES 1999–2018
Luyao Dai,Ruoxuan Li,Qian Hao,Yaohui Zhang,Huafeng Kang,Xiaobin Ma,Yafan Song +6 more
TL;DR: It is necessary to screen patients with CHD for BC and monitor BC survivors for the long-term risk of developing CHD, as this study demonstrates the close relationship between CHD and female BC.
1
The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study.
Peizhuo Yao,Yanbin Liu,Haitao Guan,Huafeng Kang,Di Liu,Yan Diao,Xiaobin Ma,Weili Min,Changyou Shan,Yang Zhao,Fang Zhao,Yuanyuan Chen,Dong Xiao,Qing She,Youhuai Liu,Yinbin Zhang,Shuqun Zhang +16 more
TL;DR: The combination of anlotinib and EC-T chemotherapy demonstrated tolerable side effects in the neoadjuvant treatment of early TNBCs, and provides additional rationale for using anlotinib plus docetaxel-epirubicin-based chemotherapy regimen in patients with early-stage TNBCs.
Integrated pan-cancer analysis and experimental verification of the roles of meiotic nuclear divisions 1 in breast cancer.
Zhen Zhai,Zhiwei Cui,Yu Zhang,Ping Song,Jinpeng Wu,Zengqi Tan,Shuai Lin,Xiaobin Ma,Feng Guan,Huafeng Kang +9 more